Skip to main content
. 2021 Apr 17;6(7):1810–1828. doi: 10.1016/j.ekir.2021.04.003

Table 9.

Overview of TEAEs—roxadustat through Week 52 or end of study (safety analysis set)

Parameter Roxadustat
Roxadustat
Pooled roxadustat
(comparative) (n = 131)
(reference) (n = 70)
(n = 201)
n (%) n (%) n (%)
TEAE 115 (87.8%) 63 (90.0%) 178 (88.6%)
Serious TEAE 34 (26.0%) 19 (27.1%) 53 (26.4%)
TEAE leading to withdrawal of treatment 26 (19.8%) 14 (20.0%) 40 (19.9%)
Death 0 2 (2.9%) 2 (1.0%)

TEAE, treatment-emergent adverse event.